Results 101 to 110 of about 60,894 (286)

TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth.

JCI Insight, 2017
Infection is the most common cause of mortality in early life, and immunization is the most promising biomedical intervention to reduce this burden. However, newborns fail to respond optimally to most vaccines.
David J. Dowling, S. V. van Haren, A. Scheid, Ilana Bergelson, Dhohyung Kim, Christy J Mancuso, W. Foppen, A. Ozonoff, L. Fresh, Terese B Theriot, A. Lackner, R. Fichorova, D. Smirnov, J. Vasilakos, Joe M Beaurline, M. Tomai, C. Midkiff, X. Alvarez, J. Blanchard, Margaret H. Gilbert, P. Aye, O. Levy   +21 more
semanticscholar   +1 more source

Escherichia coli in the production of biopharmaceuticals

Biotechnology and Applied Biochemistry, Volume 72, Issue 2, Page 528-541, April 2025.
Abstract Escherichia coli has shouldered a massive workload with the discovery of recombinant DNA technology. A new era began in the biopharmaceutical industry with the production of insulin, the first recombinant protein, in E. coli and its use in treating diabetes. After insulin, many biopharmaceuticals produced from E. coli have been approved by the
İbrahim İncir, Özlem Kaplan
wiley   +1 more source

Should Pneumococcal Serotype 3 Be Included in Serotype-Specific Immunoassays?

Vaccines, 2019
Since the introduction of the 13-valent pneumococcal conjugate vaccine, a number of studies have demonstrated the limited efficacy of the pneumococcal serotype 3 component of this vaccine. Evidence from seven countries (Denmark, France, Greece, Portugal,
Ezra Linley, Abigail Bell, Jenna F. Gritzfeld, Ray Borrow   +3 more
doaj   +1 more source

Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine.

Clinical Infectious Diseases, 2016
BACKGROUND Antibiotic-nonsusceptible invasive pneumococcal disease (IPD) decreased substantially after the US introduction of the pediatric 7-valent pneumococcal conjugate vaccine (PCV7) in 2000.
S. Tomczyk, R. Lynfield, W. Schaffner, A. Reingold, L. Miller, S. Petit, C. Holtzman, S. Zansky, A. Thomas, J. Baumbach, L. Harrison, M. Farley, B. Beall, L. McGee, R. Gierke, Tracy Pondo, L. Kim   +16 more
semanticscholar   +1 more source

Risk of Serious Infections in Patients Treated With Biologic or Targeted‐synthetic Disease Modifying Antirheumatic Drugs in Qatar

Immunity, Inflammation and Disease, Volume 13, Issue 4, April 2025.
This study investigates the risk of serious infections (SIs) in patients treated with biologic or targeted‐synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) in Qatar. Out of 1092 patients, 86 (7.9%) experienced SIs, with adalimumab and infliximab associated with higher SI rates.
Sreethish Sasi, Hamad Abdel Hadi, Masautso Chaponda, Reem El Ajez, Mohamed Ataelmanan, Sief Khasawneh, Hind Saqallah, Maisa Ali, Nabeel Abdulla, Javed Iqbal, Ali S. Omrani, Muna Al Maslamani, Abdullatif Al‐Khal   +12 more
wiley   +1 more source

Vaccination dilemma on an evolving social network [PDF]

arXiv, 2019
Vaccination is crucial for the control of epidemics. Yet it is a social dilemma since non-vaccinators can benefit from the herd immunity created by the vaccinators. Thus the optimum vaccination level is not reached via voluntary vaccination at times.
arxiv  

Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

PLoS ONE, 2017
Background The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed based on the results of immunogenicity studies and correlates of protection derived from randomized clinical trials of the 7-valent conjugate pneumococcal vaccine.
Á. Domínguez, P. Ciruela, S. Hernández, J. García-García, N. Soldevila, C. Izquierdo, F. Moraga-Llop, A. Díaz, Mariona F. de Sevilla, S. González-Peris, M. Campins, S. Uriona, J. Martínez-Osorio, A. Solé-Ribalta, G. Codina, C. Esteva, A. Planes, C. Muñoz-Almagro, L. Salleras   +18 more
semanticscholar   +1 more source

Beyond Childhood: Adult and Adolescent Sickle Cell Disease and Outcomes in Northern Ghana

eJHaem, Volume 6, Issue 2, April 2025.
ABSTRACT Background Adults and adolescents face different barriers to healthcare utilization compared to children. Objective To describe adult and adolescent sickle cell disease (SCD) and outcomes in northern Ghana. Methods This was a retrospective cohort study of SCD patients aged 13 years and above, admitted between January 1, 2021 and December 31 ...
Kwadwo Faka Gyan, Solomon Gyabaah, Eunice Agyeman Ahmed, Lesley Osei, Mohammed Najeeb Naabo, Michael Asiedu Owiredu, Yaw Obeng Opare‐Addo, Jessey Mahama Holu, Ohene Kwaku Opare‐Sem   +8 more
wiley   +1 more source

Dynamic Vaccination Game in a Heterogeneous Mixing Population [PDF]

, 2019
Opposition to vaccination has long been a non-negligible public health phenomenon resulted from people's varied perceptions toward vaccination (e.g., vaccine-phobia). This paper investigates the voluntary vaccination behavior of a heterogeneous population during an epidemic outbreak, where each individual makes its own vaccination decision to minimize ...
arxiv   +1 more source

An outbreak of pneumococcal meningitis among older children (≥5 years) and adults after the implementation of an infant vaccination programme with the 13-valent pneumococcal conjugate vaccine in Ghana

BMC Infectious Diseases, 2016
BackgroundAn outbreak of pneumococcal meningitis among non-infant children and adults occurred in the Brong-Ahafo region of Ghana between December 2015 and April 2016 despite the recent nationwide implementation of a vaccination programme for infants ...
B. Kwambana-Adams, F. Asiedu-Bekoe, B. Sarkodie, O. K. Afreh, G. K. Kuma, G. Owusu-Okyere, Ebenezer Foster-Nyarko, S. Ohene, Charles Okot, A. Worwui, C. Okoi, Madikay Senghore, Jacob K Otu, Chinelo Ebruke, R. Bannerman, Kwame Amponsa-Achiano, D. Opare, Gemma L. Kay, Timothy S Letsa, O. Kaluwa, E. Appiah-Denkyira, V. Bampoe, Syed M. A. Zaman, M. Pallen, U. d’Alessandro, J. Mwenda, M. Antonio   +26 more
semanticscholar   +1 more source